Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Dec 19, 2025 · Filed Dec 23, 2025
Incyte's Principal Accounting Officer sold $277K of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$277,400
Shares × reported transaction price
52 days after results of Oct 28, 2025, 53 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $102.69 on Dec 19, 2025, 86% above its 52-week low and 5% below its high, after a 2% drop over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 90% of the way up, from 250 adjusted closes. 30 trading days earlier: $105.20 on Nov 6, 2025. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, 2 days before this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.0% | -0.1% | -1.8% |
| 30 days | +4.1% | +0.1% | +4.0% |
| 90 days | -10.4% | -4.7% | -5.6% |
| 180 days | +2.7% | +8.2% | -5.5% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
